



ISO 13485:2016 | ISO 9001:2015 | ISO 45001:2018 | W.H.O. G.M.P. | CE
certified company



To,
Department of Corporate Service
BSE Limited,

Thursday, November 14, 2024

Registered Office : Floor 25, P. J. Towers,
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.
T: 2272 1233 / 1234 | F: 2272 3121 / 3719 | www.bseindia.com

Subject : Approval of Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2024.

Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380

Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2024.
- 2). Statement of Assets and Liabilities for the half year ended September 30, 2024.
- 3). Cash Flow Statement for the half year ended September 30, 2024.
- 4). Limited Review Report for the quarter and half year ended September 30, 2024.

Kindly take the same on your record.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**




**MAHIMA
BATHWAL**

Digitally signed by
MAHIMA
BATHWAL
Date: 2024.11.14
16:09:20 +05'30'

Mahima BATHWAL
Membership No. ACS A35069
Company Secretary & Compliance Officer

Enclosures : as mentioned above.



Registered Office
F-29, MIDC, Murbad, Thane 421401.
MAHARASHTRA.
912524222905 Fax 912524222905

Manufacturing Facility
B-17 / F-29 / F-22 MIDC, Murbad,
Thane 421401. MAHARASHTRA.
2524223200 Fax 912524 222872

Sales Office - Mumbai
1st Floor, Palai Complex CHS Ltd.,
Bhandarkar Road, Matunga (East),
Mumbai 400019. MAHARASHTRA.
912224102876 Fax 912224161261

Sales Office - Bengaluru
No.12/42, Udhani Layout,
Off. Cambridge Road, Halasur,
Bengaluru 560008. KARNATAKA.
9180 25577791 Fax 9180 25577792

Sales Office - Kolkata
Flat No. N-1, Ground Floor, 385,
Purbachal, Kalitala Road, P.S.Kasba,
Kolkata 700078. WEST BENGAL.
91 3324844875 Fax 91 3324844875

www.centenialindia.com | ISO 9001 : 2015 / ISO 13485 : 2016 certified company

Statement of Standalone Un-Audited Financial Results for the Quarter and Half year ended September 30, 2024

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2024 (Unaudited)	30/06/2024 (Unaudited)	30/09/2023 (Unaudited)	30/09/2024 (Unaudited)	30/09/2023 (Unaudited)	31/03/2024 (Audited)
I	Revenue from Operations	1427.24	1373.73	1309.61	2800.97	2675.52	5118.89
II	Other Income	6.48	0.03	2.35	6.51	2.95	12.61
III	Total Revenue (I + II)	1433.72	1373.76	1311.96	2807.48	2678.47	5131.50
IV	Expenses :						
	(a) Cost of Material Consumed	408.78	537.02	437.85	945.80	907.56	2011.60
	(b) Purchase of Stock-in-Trade						
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	152.92	(54.32)	43.00	98.61	66.57	(305.84)
	(d) Employee Benefits Expenses	279.73	282.44	263.27	562.17	553.66	1133.33
	(e) Finance Cost	52.52	53.05	52.49	105.57	100.95	246.89
	(f) Depreciation and Amortisation Expenses	109.22	79.23	31.90	188.45	61.91	138.79
	(g) Other Expenses	413.64	436.49	451.08	850.13	916.47	1779.43
	Total Expenses (IV)	1416.81	1333.91	1279.59	2750.73	2607.12	5004.20
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	16.91	39.85	32.37	56.75	71.35	127.30
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	16.91	39.85	32.37	56.75	71.35	127.30
VIII	Tax Expense :						
	(1) Current Tax	4.25	10.03	8.74	14.28	18.55	24.25
	(2) Deferred tax	-	-	-	-	-	(10.39)
	Total Tax Expenses	4.25	10.03	8.74	14.28	18.55	13.86
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	12.66	29.82	23.63	42.47	52.80	113.44
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	12.66	29.82	23.63	42.47	52.80	113.44
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	12.66	29.82	23.63	42.47	52.80	113.44
XVI	Details of Equity share capital						
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
XVII	Earnings Per Equity Share (for Continuing operation) :						
	(a) Basic	0.35	0.82	0.65	1.16	1.45	3.11
	(b) Diluted	0.35	0.82	0.65	1.16	1.45	3.11
XVIII	Earnings Per equity share (for Discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XIX	Earnings Per Equity Share (for Discontinued & Continuing operation):						
	(a) Basic	0.35	0.82	0.65	1.16	1.45	3.11
	(b) Diluted	0.35	0.82	0.65	1.16	1.45	3.11

Notes:

- The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2024 ("Statement") is, as reviewed and recommended by the Audit Committee, considered and approved by the Board of Directors at its meeting held on November 14, 2024.
- The Statement is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and other accounting principles generally accepted in India.
- The Statement is subjected to 'limited review' by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion in Limited Review of the Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2024.
- The Management has identified the reportable segments in accordance with the requirements of IND AS-108 "Operating Segments", and decided that the Company has only one reportable business segment "Medical Devices".
- The Company has considered internal and external information upto the date of approval of the Statement in assessing the recoverability of financial and non-financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these Statement.
- The previous period figures have been regrouped / rearranged wherever necessary to make it comparable with the current period.
- The Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2024 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.



for CENTENIAL SURGICAL SUTURE LTD.

VIJAY KALIDAS
MAJREKAR

Digitally signed by VIJAY KALIDAS MAJREKAR
Date: 2024.11.14 15:55:49 +05'30'

Vijay MAJREKAR
Managing Director & Chief Executive Officer

DIN : 00804808

Place : Mumbai, Maharashtra


Date : November 14, 2024

Statement of Assets and Liabilities

Rs. In Lakhs			
	Particulars	As at September 30, 2024 Unaudited	As at March 31, 2024 Audited
I	ASSETS		
1)	Non-current assets		
	a) Property, Plant and Equipment	1,850.05	1017.42
	b) Right to Use Assets	226.36	259.28
	c) Other Intangible assets	0.47	0.53
	d) Financial assets		
	(i) Loans	-	-
	(ii) Other financial assets	45.99	46.99
	e) Deferred tax assets (net)	-	-
	f) Income-tax assets (net)	25.94	24.22
	g) Other non-current assets	34.92	34.92
	Total Non-current assets (1)	2,183.73	1383.35
2)	Current assets		
	a) Inventories	4,213.55	4251.54
	b) Financial assets	-	-
	(i) Trade receivables	2,012.20	1880.44
	(ii) Cash and cash equivalents	115.37	68.46
	(iii) Bank balances other than (ii) above	-	-
	(iv) Loans	-	-
	(v) Other current financial assets	-	-
	c) Other current assets	182.03	331.41
	Total Current assets (2)	6,523.14	6531.86
	TOTAL ASSETS (I = 1 + 2)	8,706.87	7915.21
II	EQUITY & LIABILITIES		
1)	Equity		
	a) Equity Share capital	542.43	542.43
	b) Other Equity	2,721.88	2,679.39
	Total Equity (1)	3,264.31	3221.83
2)	Liabilities		
	Non-current liabilities		
	a) Financial Liabilities		
	(i) Other financial liabilities	2,293.10	1395.97
	b) Long-term provisions	-	-
	c) Deferred tax liabilities (net)	12.43	12.43
	Total Non-current liabilities	2,305.53	1408.40
	Current liabilities		
	a) Financial Liabilities		
XVI	(i) Trade payables	2,267.47	2415.72
	(ii) Other current financial liabilities	342.68	445.23
	b) Other current liabilities	526.88	424.04
XVII	c) Short-term provisions	-	-
	Total Current liabilities	3,137.03	3284.99
	Total Liabilities (2)	5,442.56	4693.38
XVIII	TOTAL EQUITY AND LIABILITIES (II = 1 + 2)	8,706.87	7915.21

Cash Flow Statement for the Quarter and Half Year ended September 30, 2024

Particulars	Rs. In Lakhs	
	As at September 30, 2024 UNAUDITED	As at March 31, 2024 Audited
A. Cash flow from operating activities		
Net Profit before tax	56.75	127.30
Adjustments for :		
Depreciation and amortisation expense	188.45	138.79
Interest income	(0.08)	(8.03)
Finance Cost	105.57	246.89
Exchange gain	(4.41)	(4.56)
Provision for Leave encashment	-	-
Provision for Gratuity	34.92	34.92
Sundry balances written back/written-off	-	-
Operating profit before working capital changes	381.20	535.31
Adjustments for :		
Decrease / (Increase) in inventories	37.99	(527.28)
Decrease / (Increase) in trade receivable	(131.76)	178.91
Decrease / (Increase) in long term loans and advances and other receivables	-	-
Decrease / (Increase) in financials and non-financial assets	1.00	(32.84)
Decrease / (Increase) in other assets and receivables	149.38	(210.97)
(Decrease) / Increase in trade and other payables	749.17	719.35
Cash generated from operations	1,186.98	662.48
Income tax refund / (paid)	(16.00)	(41.00)
Net cash (used in) / generated from operating activities	1,170.98	621.47
B. Cash flow from investing activities		
Acquisition of fixed assets and capital work in progress	(988.08)	(769.60)
Proceeds from sale of investments	-	-
Interest income on fixed deposits and other advances & exchange difference	(30.42)	(22.33)
Net cash (used in) / generated from investing activities	(1,018.50)	(791.94)
C. Cash flow from financing activities		
Finance Cost	(105.57)	(246.89)
Proceeds from Short term borrowings	-	452.83
Net cash (used in) / generated from financing activities	(105.57)	205.93
Net (decrease) / increase in cash and cash equivalents (A+B+C)	46.91	35.46
Cash and cash equivalents as at the beginning of year	68.46	33.00
Cash and cash equivalents at the end of year	115.37	68.46
Components of cash and cash equivalents		
Cash in hand	3.39	1.46
Balance with scheduled banks in current accounts	111.98	67.00
Total	115.37	68.46



Independent Auditor's Review Report on Standalone Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements [LODR]) Regulations, 2015, as amended.

Review Report to

The Board of Directors of CENTENIAL SURGICAL SUTURE LTD.

Registered Office : F-29, M.I.D.C., Murbad, Thane 421401. MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of **CENTENIAL SURGICAL SUTURE LIMITED** ("the Company") for the quarter and half year ended September 30, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR), Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- b. This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on November 14, 2024 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- c. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M/s. MAHESH CHANDRA & ASSOCIATES**
CHARTERED ACCOUNTANTS

[Firm Registration No.: 112334W]

Vipul
Vishnu
Awaghade

Digitally signed
by Vipul Vishnu
Awaghade
Date: 2024.11.14
15:49:59 +05'30'

VIPUL AWAGAHDE

Partner

[Membership No.174518]

UDIN: 24174518BKAPHT4695

Date : November 14, 2024

Place : Mumbai, MAHARASHTRA.